Mission Statement
Center for Pathophysiology, Infectiology and Immunology
A number of research initiatives and scientific achievements of the » Medical University of Vienna originate from the research area immunology/allergology/infectiology. To strengthen this successful research field further, the University defined in its development plan 2009 immunology/allergology/infectiology as one of its 4 main research clusters. As organizational measure, the University founded the Center for Pathophysiology, Infectiology and Immunology (CePII) that concentrates most of the research laboratories of the preclinical school working in pathophysiology, infectiology and immunology. Within the Center the research laboratories are substructured in 4 institutes to use more efficiently the resources and to better plan common activities:
» Institute for Hygiene and Applied Immunology [HAI]
» Institute of Immunology [IFI]
» Institute for Pathophysiology and Allergy Research [IPA]
» Institute for Specific Prophylaxis and Tropical Medicine [ISPTM]
» more information about the CePII and research area immunology/allergology/infectiology
Events
ECI 2021 - Goes Virtual The Scientific Program Committee is already hard at work to adapt the program to the virtual format in order to guarantee an event that covers the full spectrum of immunological-related research with a slate of exceptional keynote and plenary sessions featuring two Nobel Laureates and a line-up of internationally renowned scientists. Main and regular symposia sessions and a host of joint guest symposia will “open doors” to societies working in related fields. And, as could be expected, the latest developments regarding COVID-19 will feature prominently in several sessions and two specific symposia dedicated to the pandemic. Further Information:
News
Die Aktivierungsinduzierte Cytidin-Deaminase (AID) und sogenannte APOBEC-Proteine stellen gemeinsam mit ihren vielfältigen Wirkmechanismen einen wichtigen Faktor des körpereigenen Abwehrsystems dar und bieten schnellen und effektiven Schutz gegen eine Vielzahl von DNA- und RNA-Viren. Dabei fällt dem AID die Aufgabe zu, die menschliche Immunantwort zu stärken, APOBECs wiederum können das jeweilige Virus hemmen. Ein Forschungsteam der MedUni Wien mit Anastasia Meshcheryakova, Diana Mechtcheriakova und Peter Pietschmann vom Institut für Pathophysiologie und Allergieforschung zeigte nun die möglichen Zusammenhänge zwischen AID/APOBECs und dem SARS-CoV-2 Virus, im besonderem im Zusammenhang mit dem patientenspezifischen Verlauf der COVID-19 Erkrankung, auf.
